@article{2999770,
    title = "Management of anaphylaxis due to COVID-19 vaccines in the elderly",
    author = "Bousquet, J. and Agache, I. and Blain, H. and Jutel, M. and Ventura, M.T. and Worm, M. and Del Giacco, S. and Benetos, A. and Bilo, B.M. and Czarlewski, W. and Abdul Latiff, A.H. and Al-Ahmad, M. and Angier, E. and Annesi-Maesano, I. and Atanaskovic-Markovic, M. and Bachert, C. and Barbaud, A. and Bedbrook, A. and Bennoor, K.S. and Berghea, E.C. and Bindslev-Jensen, C. and Bonini, S. and Bosnic-Anticevich, S. and Brockow, K. and Brussino, L. and Camargos, P. and Canonica, G.W. and Cardona, V. and Carreiro-Martins, P. and Carriazo, A. and Casale, T. and Caubet, J.-C. and Cecchi, L. and Cherubini, A. and Christoff, G. and Chu, D.K. and Cruz, A.A. and Dokic, D. and El-Gamal, Y. and Ebisawa, M. and Eberlein, B. and Farrell, J. and Fernandez-Rivas, M. and Fokkens, W.J. and Fonseca, J.A. and Gao, Y. and Gavazzi, G. and Gawlik, R. and Gelincik, A. and Gemicioğlu, B. and Gotua, M. and Guérin, O. and Haahtela, T. and Hoffmann-Sommergruber, K. and Hoffmann, H.J. and Hofmann, M. and Hrubisko, M. and Illario, M. and Irani, C. and Ispayeva, Z. and Ivancevich, J.C. and Julge, K. and Kaidashev, I. and Khaitov, M. and Knol, E. and Kraxner, H. and Kuna, P. and Kvedariene, V. and Lauerma, A. and Le, L.T.T. and Le Moing, V. and Levin, M. and Louis, R. and Lourenco, O. and Mahler, V. and Martin, F.C. and Matucci, A. and Milenkovic, B. and Miot, S. and Montella, E. and Morais-Almeida, M. and Mortz, C.G. and Mullol, J. and Namazova-Baranova, L. and Neffen, H. and Nekam, K. and Niedoszytko, M. and Odemyr, M. and O’Hehir, R.E. and Okamoto, Y. and Ollert, M. and Palomares, O. and Papadopoulos, N.G. and Panzner, P. and Passalacqua, G. and Patella, V. and Petrovic, M. and Pfaar, O. and Pham-Thi, N. and Plavec, D. and Popov, T.A. and Recto, M.T. and Regateiro, F.S. and Reynes, J. and Roller-Winsberger, R.E. and Rolland, Y. and Romano, A. and Rondon, C. and Rottem, M. and Rouadi, P.W. and Salles, N. and Samolinski, B. and Santos, A.F. and S Sarquis, F. and Sastre, J. and M. G. A. Schols, J. and Scichilone, N. and Sediva, A. and Shamji, M.H. and Sheikh, A. and Skypala, I. and Smolinska, S. and Sokolowska, M. and Sousa-Pinto, B. and Sova, M. and Stelmach, R. and Sturm, G. and Suppli Ulrik, C. and Todo-Bom, A.M. and Toppila-Salmi, S. and Tsiligianni, I. and Torres, M. and Untersmayr, E. and Urrutia Pereira, M. and Valiulis, A. and Vitte, J. and Vultaggio, A. and Wallace, D. and Walusiak-Skorupa, J. and Wang, D.-Y. and Waserman, S. and Yorgancioglu, A. and Yusuf, O.M. and Zernotti, M. and Zidarn, M. and Chivato, T. and Akdis, C.A. and Zuberbier, T. and Klimek, L.",
    journal = "Allergy: European Journal of Allergy and Clinical Immunology",
    year = "2021",
    volume = "76",
    number = "10",
    pages = "2952-2964",
    publisher = "John Wiley and Sons Inc",
    doi = "10.1111/all.14838",
    keywords = "epinephrine;  SARS-CoV-2 vaccine;  epinephrine, airway;  anaphylaxis;  Article;  breathing;  circulation;  comorbidity;  coronavirus disease 2019;  disability;  disease severity;  exposure;  geriatric patient;  human;  polypharmacy;  risk factor;  vaccination;  aged;  anaphylaxis;  male, Aged;  Anaphylaxis;  COVID-19;  COVID-19 Vaccines;  Epinephrine;  Humans;  Male;  SARS-CoV-2",
    abstract = "Older adults, especially men and/or those with diabetes, hypertension, and/or obesity, are prone to severe COVID-19. In some countries, older adults, particularly those residing in nursing homes, have been prioritized to receive COVID-19 vaccines due to high risk of death. In very rare instances, the COVID-19 vaccines can induce anaphylaxis, and the management of anaphylaxis in older people should be considered carefully. An ARIA-EAACI-EuGMS (Allergic Rhinitis and its Impact on Asthma, European Academy of Allergy and Clinical Immunology, and European Geriatric Medicine Society) Working Group has proposed some recommendations for older adults receiving the COVID-19 vaccines. Anaphylaxis to COVID-19 vaccines is extremely rare (from 1 per 100,000 to 5 per million injections). Symptoms are similar in younger and older adults but they tend to be more severe in the older patients. Adrenaline is the mainstay treatment and should be readily available. A flowchart is proposed to manage anaphylaxis in the older patients. © 2021 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd."
}